Myofascial Pain Syndrome of the Abdominal Wall for the Busy Clinician

Clinical Obstetrics and Gynecology

Volumn 46, Issue 4, 2003, Pages 783-788

  Sharp, Howard T ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ANTIINFLAMMATORY AGENT; BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL WALL; CHRONIC PAIN; CLINICAL PRACTICE; HUMAN; HYSTERECTOMY; MYOFASCIAL PAIN; PATHOPHYSIOLOGY; PATIENT CARE; PELVIS PAIN SYNDROME; REVIEW; SKELETAL MUSCLE; TRAINING;

ABDOMEN; CHRONIC DISEASE; FEMALE; GYNECOLOGY; HUMANS; MYOFASCIAL PAIN SYNDROMES; PALPATION; PELVIC PAIN; PHYSICAL EXAMINATION;

EID: 0242509860     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200312000-00007     Document Type: Review

References (19)

1. Rosen NB. The myofascial syndromes. Phys Med Rehabil Clin N Am. 1993;4:41-63.
2. Skootsky SA, Jaeger B, Oye RK. Prevalence of myofascial pain in general internal medicine practice. West J Med. 1989;151:157-160.
3. Kaergaard A, Andersen JH. Musculoskeletal disorders of the neck and shoulders in female sewing machine operators: prevalence, incidence and prognosis. Occup Environ Med. 2000;57:528-534.
4. Peterson HB, Hulka JF, Phillips JM. American Association of Gynecologic Laparoscopists' 1988 membership survey on operative laparoscopy. J Reprod Med. 1990;35:587-589.
5. Slocumb JC. Neurological factors in chronic pelvic pain: trigger points and the abdominal pelvic pain syndrome. Am J Obstet Gynecol. 1985;149:536-543.
6. The American College of Obstetricians and Gynecologists. Quality and Improvement in Obstetrics and Gynecology. Washington DC. The American College of Obstetricians and Gynecologists, 1994.
7. Borg-Stein J, Simons DG. Myofascial pain. Arch Phys Med Rehabil. 2002; 83: S40-S47.
8. nd ed. Baltimore: Williams & Wilkens; 1999.
9. Good MG. Pseudo-appendicitis. Acta Med Scand. 1950;138:285-292.
10. Theobold GW. The role of the cerebral cortex in the apperception of pain. Lancet. 1949;2:41-47.
11. Mayer EA, Raybould HE. Role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology. 1990;99: 1688-1704.
12. Chang FY, Chey WY, Ouyang A. Effect of transcutaneous nerve stimulation on esophageal function in normal subjects-evidence for somatovisceral reflex. Am J Chin Med. 1996;185-192.
13. Fine PG, Milano R, Hare BD. The effects of myofascial trigger point injections are naloxone reversible. Pain. 1988;32:15-20.
14. Mense S. Pathophysiologic basis of muscle pain syndromes. Phys Med Rehabil Clin North Am. 1997;8:23-53.
15. Simons DG, Hong CZ, Simons LS. Endplate potentials are common to midfiber myofascial trigger points. Am J Phys Med Rehabil. 2002;81:212-222.
16. Simons DG, Stolov WC. Microscopic features and contraction of palpable bands in canine muscle. Am J Phys Med. 1976;55: 65-88.
17. Hoheisal U, Mense S, Simons DG, et al. Appearance of new receptive fields in rat dorsal horn neurons following noxious stimulation of skeletal muscle: a model for referral of muscle pain? Neurosci Lett. 1993;153:9-12.
18. Kraus H. Clinical treatment of back and Neck pain. McGraw Hill, New York, 1970.
19. Hameroff SR, Crago BR, Blitt CD, et al. Comparison of bupivicaine, etidocaine, and saline for trigger point therapy. Anesth Analg. 1981;60:752-755.